Anthera Financial Statements From 2010 to 2025
| ANTH Stock | USD 0.0001 0.00 0.00% |
Check Anthera Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anthera Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Anthera financial statements analysis is a perfect complement when working with Anthera Pharmaceuticals Valuation or Volatility modules.
Anthera |
Anthera Pharmaceuticals Company Number Of Shares Shorted Analysis
Anthera Pharmaceuticals' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Anthera Pharmaceuticals Number Of Shares Shorted | 2.02 M |
Most of Anthera Pharmaceuticals' fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Anthera Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Anthera Pharmaceuticals has 2.02 M of outstending shares currently sold short by investors. This is 37.02% lower than that of the Biotechnology sector and 60.47% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 57.18% higher than that of the company.
Anthera Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Anthera Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Anthera Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Anthera Pharmaceuticals competition to find correlations between indicators driving Anthera Pharmaceuticals's intrinsic value. More Info.Anthera Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Anthera Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Anthera Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Anthera Pharmaceuticals Financial Statements
Investors use fundamental indicators, such as Anthera Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Anthera Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas. Anthera Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 21 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Anthera Pink Sheet
Anthera Pharmaceuticals financial ratios help investors to determine whether Anthera Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Anthera with respect to the benefits of owning Anthera Pharmaceuticals security.